Home・Список акций・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

3.15 -4.55

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.27

Макс.

3.34

Ключевые показатели
By Trading Economics
Доход	-131M -249M
Продажи	1.2M 7.7M
Прибыль на акцию	-0.25
Рентабельность продаж	-3,240.013
Сотрудники	600
EBITDA	-10M -113M

Рекомендации
By TipRanks
Рекомендации	Нейтрально
Прогноз на 12 месяцев	+97.57% upside

Дивиденды
By Acuity
Следующий отчет о доходах	4 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	77M 1.8B
Предыдущая цена открытия	7.7
Предыдущая цена закрытия	3.15

Новостные настроения

By Acuity

48%

52%

168 / 340 Рейтинг в Healthcare

Recursion Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

12 авг. 2026 г., 19:56 UTC

Recursion Pharmaceuticals Inc is trading lower, reflecting a decline from Tuesday's close. The stock remains above its 20-day moving average despite today's pullback.

11 авг. 2026 г., 19:36 UTC

News

Recursion Pharmaceuticals Inc. is higher today amid positive market sentiment and over $500 million in milestone payments from partnerships with Genentech/Roche and Sanofi.

10 авг. 2026 г., 20:06 UTC

Social Media

Recursion Pharmaceuticals Inc is higher Monday amid ongoing interest, despite social media concerns about its clinical pipeline and integration challenges with Exscientia.

7 авг. 2026 г., 23:26 UTC

Recursion Pharmaceuticals Inc. shares have been roughly flat in after-market trading, with minimal fluctuations since Friday's close. The stock remains above its 20-day moving average.

6 авг. 2026 г., 23:26 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid a strengthening U.S. Dollar.

5 авг. 2026 г., 23:41 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, amid declining sentiment in US markets despite positive momentum in Asian indices.

4 авг. 2026 г., 23:31 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours following a volatile session with no specific news to explain the movement.

3 авг. 2026 г., 20:03 UTC

Correlated Moves

News

Recursion Pharmaceuticals Inc shares are higher amid strong market sentiment, supported by a rise in the Russell 2000 Index and notable intraday volatility.

31 июл. 2026 г., 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

30 июл. 2026 г., 23:26 UTC

Recursion Pharmaceuticals Inc. shares were roughly flat in after-market hours, trading within a narrow range since Thursday's close, significantly below its 20-day moving average.

29 июл. 2026 г., 22:51 UTC

Recursion Pharmaceuticals Inc is higher in after-market trading, reflecting broader market gains amid the Federal Reserve's decision to maintain interest rates.

28 июл. 2026 г., 23:11 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares declined in after-market hours, influenced by a broader market downturn and declines in tech stocks amid AI investment concerns.

27 июл. 2026 г., 23:46 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower in after-market trading, reflecting broader market trends despite gains in the DAX 30 Index amid mixed results across indices.

24 июл. 2026 г., 23:11 UTC

Recursion Pharmaceuticals Inc shares rose during after-market hours, gaining momentum despite being near the lower end of their one-month trading range.

23 июл. 2026 г., 19:16 UTC

Recursion Pharmaceuticals Inc. shares are trading roughly flat, remaining below their 20-day moving average amid limited upward momentum in broader market dynamics.

22 июл. 2026 г., 23:36 UTC

Recursion Pharmaceuticals Inc. shares are near unchanged in after-market hours. The stock remains below its 20-day moving average amid rising crude oil prices.

21 июл. 2026 г., 23:51 UTC

Recursion Pharmaceuticals Inc's shares are lower in after-market hours, settling down from Tuesday's close without any specific news to explain the movement.

20 июл. 2026 г., 19:46 UTC

Correlated Moves

Recursion Pharmaceuticals is declining, continuing a trend from previous sessions, amid broader declines in the ARK Genomic Revolution ETF and Russell 2000 Index.

Сравнение c конкурентами

Изменение цены

Recursion Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

97.57% рост

Прогноз на 12 месяцев

Средняя 6.5 USD 97.57%

Максимум 8 USD

Минимум 5.5 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Recursion Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

4 ratings

Покупка

Удержание

Продажа

Основано на мнении 4 аналитиков, присваивавших рейтинги акциям Recursion Pharmaceuticals Inc – Данные за последние 3 месяца.

Настроения

By Acuity

168 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.